Format

Send to

Choose Destination
Blood Adv. 2020 Feb 11;4(3):445-448. doi: 10.1182/bloodadvances.2019001182.

A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia.

Author information

1
Department of Pathology, Massachusetts General Hospital, Boston, MA.
2
Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA.
3
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
4
Harvard Medical School, Harvard University, Boston, MA.
5
Department of Pathology, Brigham and Women's Hospital, Boston, MA.
6
Division of Hematology, Massachusetts General Hospital Cancer Center, Boston, MA.
7
Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, MA; and.
8
Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA.

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center